Group One Trading’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-10,100
| Closed | -$26.2K | – | 8510 |
|
|
2023
Q2 | $26.2K | Sell |
10,100
-6,500
| -39% | -$23.2K | ﹤0.01% | 5781 |
|
|
2023
Q1 | $67.7K | Buy |
16,600
+14,900
| +876% | +$68.9K | ﹤0.01% | 4619 |
|
|
2022
Q4 | $8.53K | Sell |
1,700
-3,200
| -65% | -$20.1K | ﹤0.01% | 6084 |
|
|
2022
Q3 | $64K | Buy |
4,900
+4,700
| +2,350% | +$71.2K | ﹤0.01% | 5206 |
|
|
2022
Q2 | $3K | Buy |
+200
| New | +$2.77K | ﹤0.01% | 7342 |
|
|
2022
Q1 | – | Sell |
-9,200
| Closed | -$163K | – | 8932 |
|
|
2021
Q4 | $163K | Buy |
9,200
+7,400
| +411% | +$142K | ﹤0.01% | 5287 |
|
|
2021
Q3 | $38K | Hold |
1,800
| – | – | ﹤0.01% | 6761 |
|
|
2021
Q2 | $36K | Buy |
1,800
+1,600
| +800% | +$37.5K | ﹤0.01% | 6841 |
|
|
2021
Q1 | $6K | Buy |
200
+100
| +100% | +$2.8K | ﹤0.01% | 7210 |
|
|
2020
Q4 | $3K | Sell |
100
-200
| -67% | -$4.38K | ﹤0.01% | 6196 |
|
|
2020
Q3 | $5K | Sell |
300
-200
| -40% | -$3.65K | ﹤0.01% | 5655 |
|
|
2020
Q2 | $10K | Buy |
+500
| New | +$9.56K | ﹤0.01% | 5133 |
|
Group One Trading's NGM Position: Q2 2024 in Review
Group One Trading sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 1,052 shares — an estimated $1.67K sold.
Group One Trading first reported a position in NGM in Q3 2020 and held it in 7 quarters. The position peaked at $56K in Q3 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Group One Trading reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Group One Trading sold 1,052 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $1.67K.
- Group One Trading first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
- Group One Trading's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $56K in Q3 2022.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Group One Trading's 13F filing for Q2 2024, filed 14 Aug 2024.